Cite
HARVARD Citation
Chalker, C. et al. (2022). Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients. Cancer medicine. pp. 4104-4111. [Online].